Lymphangioleiomyomatosis (LAM) is a rare lung disease that has become more treatable thanks to dedicated efforts from researchers and patient advocacy groups. ATS Past President Gregory Downey, MD, ATSF, National Jewish Health, discusses advances in understanding and treating LAM with host Ugo Ezema, MD. What role do patient networks play and what does the future hold for research?

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are serious conditions that often affect critically ill patients in ICUs. These infections carry a high risk of mortality and are frequently caused by multidrug-resistant bacteria like MRSA. On this episode of the ATS Breathe Easy podcast, Scott Micek, PharmD, University of Health Sciences and Pharmacy in St. Louis, explains to host Eddie Qian, MD, Vanderbilt University, why treating HABP/VABP needs to be tailored to the patient, how rapid diagnostics have pros and cons, and the importance of balancing aggressive early treatment with careful reassessment.

This episode is sponsored by Innoviva Specialty Therapeutics.

When news of the Andes strain of the hantavirus broke out, the world seemed to hold its breath. But what do we know about the hantavirus? Expert Michelle Harkins, MD, University of New Mexico, discusses what the hantavirus is and how it is transmitted. She and host Ugo Ezema, MD, Tulane University, delve deeper at the ATS International Conference into how this hantavirus outbreak differs from the spread of COVID, what tests are used to detect hantavirus, and what research is happening in prevention and treatment of hantavirus.